In a study that combined vaccination with VEGF receptor tyrosine kinase (RTK) inhibitor, in a M05 mouse breast cancer model, it was shown that VCAM-1 blocking antibodies or blocking the CXCR3 receptor impaired CD8+ T cell infiltration and therapeutic efficacy (31). This evidence concerns the gene CD8A and breast carcinoma.